HRTX News and Press, Heron Therapeutics Inc. From 06/12/23

Heron Therapeutics Announces Appointment of William Forbes, Pharm.D. as Chief Development Officer PR Newswire SAN DIEGO , June 12, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the live...

2023-06-03 18:15:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-05-25 02:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-05-17 10:03:19 ET Gainers: XBiotech ( XBIT ) +32% . Impel Pharmaceuticals ( IMPL ) +30% . Immutep ( IMMP ) +14% . Corvus Pharmaceuticals ( CRVS ) +13% . Sientra ( SIEN ) +10% . Losers: Intercept Pharmaceuticals ( ICP...

2023-05-12 13:14:08 ET Gainers: GSI Technology ( GSIT ) +149% . ARS Pharmaceuticals ( SPRY ) +80% . Zapp Electric Vehicles Group Limited ( ZAPP ) +42% . AirSculpt Technologies ( AIRS ) +39% . Blue Bird Corporation ( BLBD ) +34% ....

2023-05-12 11:50:49 ET Heron Therapeutics ( NASDAQ: HRTX ) stock fell ~35% on Friday after Q1 2023 results missed estimates. Its Q1 net loss narrowed to -$32.77M, compared to -63.89M in Q1 2022. Net product sales grew 26.2% Y/Y to $29.62M but missed analysts expectat...

2023-05-12 10:03:10 ET Gainers: ARS Pharmaceuticals ( SPRY ) +77% . Dermata Therapeutics ( DRMA ) +63% . AirSculpt Technologies ( AIRS ) +27% . GlycoMimetics ( GLYC ) +14% . BioAtla ( BCAB ) +13% . Losers: Heron Thera...

2023-05-11 22:18:06 ET Heron Therapeutics, Inc. (HRTX) Q1 2023 Earnings Conference Call May 11, 2023 04:30 PM ET Company Participants Craig Collard - Chief Executive Officer David Szekeres - Executive Vice President & Chief Operating Officer Conference Call...

2023-05-11 16:03:42 ET Heron Therapeutics press release ( NASDAQ: HRTX ): Q1 GAAP EPS of -$0.27 misses by $0.07 . Revenue of $29.62M (+26.3% Y/Y) misses by $0.07M . For further details see: Heron Therapeutics GAAP EPS of -$0.27 misses by $0.07, revenue of...

Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2023 and Highlights Recent Corporate Updates PR Newswire · Net Product Sales for First Quarter of 2023 Grew 26% to $29.6 million , Compared to First Quarter Net Product Sales in 2022 ...